Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 23;16(2):127-139.
doi: 10.1016/j.jcin.2022.11.022.

Concomitant Transcatheter Edge-to-Edge Treatment of Secondary Tricuspid and Mitral Regurgitation: An Expert Opinion

Affiliations
Free article
Review

Concomitant Transcatheter Edge-to-Edge Treatment of Secondary Tricuspid and Mitral Regurgitation: An Expert Opinion

Antonio Sisinni et al. JACC Cardiovasc Interv. .
Free article

Abstract

Secondary (functional) tricuspid regurgitation (sTR) is common in patients with mitral regurgitation (MR). Because combined valvular heart disease affects long-term survival, in comparison with isolated MR or tricuspid regurgitation, it is essential to offer patients adequate treatment. Despite considerable experience, no conclusive data are yet available on the prognostic impact of concomitant tricuspid valve surgery at the time of mitral valve surgery. Emerging transcatheter treatments offer the opportunity to treat both conditions (MR and sTR) simultaneously or in a stepwise fashion. This review provides a clinical overview on available data regarding the rationale for treatment of sTR in patients with relevant MR undergoing mitral transcatheter edge-to-edge repair, focusing on clinical and anatomical selection criteria.

Keywords: concomitant treatment; mitral regurgitation; secondary tricuspid regurgitation; transcatheter mitral valve repair; tricuspid transcatheter edge-to-edge repair.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Metra has received consulting honoraria for participation in steering committees or advisory boards or for speeches from Abbott Vascular, Amgen, AstraZeneca, Bayer, Edwards, Fresenius, Novartis, and Servier. Dr Adamo has received speaker fees from Abbott Vascular and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Similar articles

Cited by

MeSH terms

LinkOut - more resources